ATRC News and Press, AtriCure Inc. From 07/28/20

Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a lead...

Quick Take Acutus Medical ( AFIB ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The firm designs and sells various catheter-based ablation tools to treat cardiac arrhythmias. AFIB is in early commercialization stage for its i...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at...

Protalix Reports Positive Topline Results for Phase III Data Protalix BioTherapeutics Inc. ( PLX ) announced positive topline data from Phase III BRIDGE clinical trial of its lead drug candidate PRX-102. This Phase III study was an open label, single arm switch-over 12 month long study a...

AtriCure (NASDAQ: ATRC ) prices underwritten offering of 3,977,273 common shares at $44.00 per share for gross proceeds of $175M. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuan...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares o...

Previously, I wrote how indiscriminate buying would be replaced with selectivity and that the market was approaching an important make-or-break moment following its rapid run-up since March. The S&P 500 remains below critical resistance, so the risk of weakness remains. However, our ...

AtriCure (NASDAQ: ATRC ) announces positive results from the CONVERGE IDE study evaluating its EPi-Sense device in a procedure called hybrid Convergent ablation to treat patients with persistent atrial fibrillation (AF). More news on: AtriCure, Inc., Healthcare stocks news, Stocks on t...

Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)...